{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pemetrexed+%28Chemotherapy%29&page=10", "query": { "intervention": "Pemetrexed (Chemotherapy)", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 381, "total_pages": 39, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pemetrexed+%28Chemotherapy%29&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pemetrexed+%28Chemotherapy%29&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T11:34:47.423Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03256136", "title": "Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2017-11-22", "completion_date": "2019-08-19", "has_results": true, "last_update_posted_date": "2020-11-04", "last_synced_at": "2026-10-14T11:34:47.423Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03256136" }, { "nct_id": "NCT00660816", "title": "Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2008-01", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2015-10-12", "last_synced_at": "2026-10-14T11:34:47.423Z", "location_count": 13, "location_summary": "Detroit, Michigan • New York, New York • Cleveland, Ohio + 3 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00660816" }, { "nct_id": "NCT02419495", "title": "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Fallopian Tube Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Ovarian Carcinoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Primary Peritoneal Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Melanoma", "Unresectable Renal Cell Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 221, "start_date": "2015-06-26", "completion_date": "2024-09-16", "has_results": false, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-10-14T11:34:47.423Z", "location_count": 5, "location_summary": "Conroe, Texas • Houston, Texas • League City, Texas + 1 more", "locations": [ { "city": "Conroe", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "League City", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419495" }, { "nct_id": "NCT04077463", "title": "A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Lazertinib", "type": "DRUG" }, { "name": "Amivantamab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 701, "start_date": "2019-09-04", "completion_date": "2028-03-27", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-10-14T11:34:47.423Z", "location_count": 18, "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "West Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04077463" }, { "nct_id": "NCT00533429", "title": "Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "enzastaurin", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2007-10", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2021-05-13", "last_synced_at": "2026-10-14T11:34:47.423Z", "location_count": 12, "location_summary": "Bentonville, Arkansas • Chicago, Illinois • Galesburg, Illinois + 9 more", "locations": [ { "city": "Bentonville", "state": "Arkansas" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Galesburg", "state": "Illinois" }, { "city": "Bloomington", "state": "Indiana" }, { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00533429" }, { "nct_id": "NCT03800134", "title": "A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 825, "start_date": "2018-12-06", "completion_date": "2028-09-11", "has_results": false, "last_update_posted_date": "2025-06-11", "last_synced_at": "2026-10-14T11:34:47.423Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Duarte, California • Orange, California + 25 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03800134" }, { "nct_id": "NCT00226577", "title": "Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2004-02", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2017-03-23", "last_synced_at": "2026-10-14T11:34:47.423Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00226577" }, { "nct_id": "NCT02489903", "title": "RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Carcinoma", "Carcinoma, Non-Small-Cell Lung", "Neuroendocrine Tumors", "Ovarian Epithelial Cancer" ], "interventions": [ { "name": "RRx-001", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Doxil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Taxane", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EpicentRx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2015-06", "completion_date": "2021-12-06", "has_results": true, "last_update_posted_date": "2025-03-17", "last_synced_at": "2026-10-14T11:34:47.423Z", "location_count": 10, "location_summary": "Palo Alto, California • West Haven, Connecticut • South Bend, Indiana + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "West Haven", "state": "Connecticut" }, { "city": "South Bend", "state": "Indiana" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02489903" }, { "nct_id": "NCT04334759", "title": "DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mesothelioma", "Pleural Mesothelioma", "Malignant Pleural Mesothelioma" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Standard Chemotherapy", "type": "DRUG" }, { "name": "Ipilimumab and Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PrECOG, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 214, "start_date": "2021-02-18", "completion_date": "2025-06-30", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-14T11:34:47.423Z", "location_count": 25, "location_summary": "La Jolla, California • Miami, Florida • Tampa, Florida + 20 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04334759" }, { "nct_id": "NCT00509366", "title": "Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Cisplatin & Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin & Pemetrexed", "type": "DRUG" }, { "name": "Docetaxel & Gemcitabine", "type": "DRUG" }, { "name": "Pemetrexed & Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2007-05", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2014-08-28", "last_synced_at": "2026-10-14T11:34:47.423Z", "location_count": 8, "location_summary": "Durham, North Carolina • Henderson, North Carolina • Laurinburg, North Carolina + 5 more", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Henderson", "state": "North Carolina" }, { "city": "Laurinburg", "state": "North Carolina" }, { "city": "Lumberton", "state": "North Carolina" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00509366" } ] }